Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an announcement.
Recce Pharmaceuticals Ltd. announced the passing of its founder, Dr. Graham JH Melrose, a pioneer in polymer chemistry and infectious diseases. His leadership and vision were instrumental in establishing Recce as a notable player in the biotech industry, focusing on innovative solutions to antibiotic resistance. Dr. Melrose’s legacy continues to inspire the company’s mission and future innovations.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. operates in the biotech industry, focusing on developing anti-infective technologies to combat antibiotic resistance. Founded in 2007 by Dr. Graham JH Melrose, the company has established a portfolio of new class anti-infectives, supported by over 40 granted patents across major pharmaceutical markets.
Average Trading Volume: 122,098
Technical Sentiment Signal: Hold
Current Market Cap: A$124.3M
Learn more about RCE stock on TipRanks’ Stock Analysis page.